Drug
empagliflozin 10mg
empagliflozin 10mg is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_4
2
67%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (33.3%)
Phase 42 (66.7%)
Trials by Status
not_yet_recruiting133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_4
Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
NCT07365358
completedphase_2
Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure
NCT03128528
completedphase_4
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
NCT02589626
Clinical Trials (3)
Showing 3 of 3 trials
NCT07365358Phase 4
Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
NCT03128528Phase 2
Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure
NCT02589626Phase 4
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3